ESR1 and prostate carcinoma: Our identification of an ERα-NEAT1 axis illustrates a mechanism whereby prostate cancer cells may develop therapeutic resistance through positive selection of an alternate nuclear receptor signalling pathway in the absence of AR or during androgen ablation therapy (Fig. 10).